{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mg+Cl", "query": { "intervention": "Mg Cl" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1446, "total_pages": 145, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mg+Cl&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T13:28:44.753Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02694978", "title": "A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Iron Deficiency Anemia" ], "interventions": [ { "name": "Ferumoxytol", "type": "DRUG" }, { "name": "FCM", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AMAG Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2014, "start_date": "2016-02-29", "completion_date": "2017-07-17", "has_results": true, "last_update_posted_date": "2023-07-25", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 100, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 83 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02694978" }, { "nct_id": "NCT03461406", "title": "A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Excessive Bleeding During Surgery" ], "interventions": [ { "name": "Fibrin Sealant Grifols", "type": "BIOLOGICAL" }, { "name": "EVICEL", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Instituto Grifols, S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": 186, "start_date": "2019-01-18", "completion_date": "2022-05-20", "has_results": true, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 12, "location_summary": "Chicago, Illinois • Michigan Center, Michigan • Albany, New York + 9 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Michigan Center", "state": "Michigan" }, { "city": "Albany", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03461406" }, { "nct_id": "NCT05274568", "title": "Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Parkinson Disease", "Multisystem Atrophy", "Healthy Volunteer" ], "interventions": [ { "name": "[18F]UCB-2897", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Invicro", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-01-31", "completion_date": "2023-10-25", "has_results": false, "last_update_posted_date": "2025-02-20", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05274568" }, { "nct_id": "NCT03278691", "title": "Ketorolac on Posterior Thoracolumbar Spinal Fusions", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Thoracolumbar Spinal Fusions" ], "interventions": [ { "name": "Saline", "type": "DRUG" }, { "name": "Ketorolac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2017-10-03", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2023-04-20", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 1, "location_summary": "Southfield, Michigan", "locations": [ { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03278691" }, { "nct_id": "NCT02041533", "title": "An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IV or Recurrent Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 541, "start_date": "2014-03-27", "completion_date": "2022-05-27", "has_results": true, "last_update_posted_date": "2023-03-02", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 36, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02041533" }, { "nct_id": "NCT06001658", "title": "Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Billiary Track Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-07-08", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06001658" }, { "nct_id": "NCT04927585", "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "env (A,B,C,A/E)/gag (C) DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "gp120 (A,B,C,A/E) Protein Vaccine", "type": "BIOLOGICAL" }, { "name": "GLA-SE adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Worcester HIV Vaccine", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 42, "start_date": "2021-07-08", "completion_date": "2023-12-07", "has_results": false, "last_update_posted_date": "2024-04-09", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927585" }, { "nct_id": "NCT01505088", "title": "Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anterior Uveitis" ], "interventions": [ { "name": "40 mg/mL Dexamethasone phosphate ophthalmic solution", "type": "DRUG" }, { "name": "Prednisolone Acetate (1%) Eyedrops", "type": "DRUG" }, { "name": "100 mM sodium citrate buffer solution", "type": "DRUG" }, { "name": "Placebo Eyedrops", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eyegate Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "12 Years to 85 Years" }, "enrollment_count": 193, "start_date": "2011-12", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2013-03-29", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01505088" }, { "nct_id": "NCT04317040", "title": "Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronavirus Disease 2019 (COVID-19)" ], "interventions": [ { "name": "Efprezimod alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 234, "start_date": "2020-04-24", "completion_date": "2020-10-20", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 10, "location_summary": "Jacksonville, Florida • Annapolis, Maryland • Baltimore, Maryland + 7 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Annapolis", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04317040" }, { "nct_id": "NCT01495624", "title": "The Effect of Systemic or Perineural Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Duration of Interscalene Block" ], "interventions": [ { "name": "ropivacaine plus dexamethasone anesthetic", "type": "OTHER" }, { "name": "ropivacaine plus saline plus dexamethasone anesthetic", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2011-12", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-01-27", "last_synced_at": "2026-09-03T13:28:44.753Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01495624" } ] }